Sangamo Therapeutics, Inc. (SGMO)

Biological Products, (No Diagnostic Substances) · market cap $53M · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Sangamo Therapeutics (SGMO) is a Richmond, CA-based cell and gene therapy company with 183 employees and a market cap of approximately $53M at a share price of ~$0.13. The company carries a broad but aging pipeline of Phase 2 assets across sickle cell disease, Parkinson's, Alzheimer's, Fabry disease, HIV, kidney transplant rejection, and Type 1 diabetes, yet has no disclosed cash balance, runway, or upcoming catalysts on the calendar. Revenue has collapsed from $176M in 2023 to $58M in 2024, while R&D spend remains elevated at $112M, implying deep and ongoing cash burn.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Plerixafor	Phase 2	Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin	Phase 2	Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery	Phase 2	Alzheimer's Disease
TX200-TR101	Phase 2	Kidney Transplant Rejection
ST-920	Phase 2	Fabry Disease
SB-728-T	Phase 2	HIV
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])	Phase 2	Idiopathic Parkinson's Disease
SB-509	Phase 2	Diabetes Mellitus, Type 1

Price & technical context

3-month

-65.5%

6-month

-71.6%

12-month

-74.5%

52-wk range

$0.10–$0.74

vs 50-day MA

-49.7%

vs 200-day MA

-70.9%

Realized vol

138.2%

Max drawdown

-96.5%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for SGMO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.